BEXIMCO Financial Statements From 2010 to 2024
| R2WA Stock | EUR 0.41 0.00 0.00% |
Check BEXIMCO PHARMAGDR financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BEXIMCO PHARMAGDR's main balance sheet or income statement drivers, such as , as well as many indicators such as . BEXIMCO financial statements analysis is a perfect complement when working with BEXIMCO PHARMAGDR Valuation or Volatility modules.
BEXIMCO |
BEXIMCO PHARMAGDR REGS Company Return On Equity Analysis
BEXIMCO PHARMAGDR's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current BEXIMCO PHARMAGDR Return On Equity | 0.12 |
Most of BEXIMCO PHARMAGDR's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BEXIMCO PHARMAGDR REGS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, BEXIMCO PHARMAGDR REGS has a Return On Equity of 0.1163. This is 100.49% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The return on equity for all Germany stocks is 137.52% lower than that of the firm.
BEXIMCO PHARMAGDR REGS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BEXIMCO PHARMAGDR's current stock value. Our valuation model uses many indicators to compare BEXIMCO PHARMAGDR value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BEXIMCO PHARMAGDR competition to find correlations between indicators driving BEXIMCO PHARMAGDR's intrinsic value. More Info.BEXIMCO PHARMAGDR REGS is rated below average in return on equity category among its peers. It is rated third in return on asset category among its peers reporting about 0.57 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for BEXIMCO PHARMAGDR REGS is roughly 1.76 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BEXIMCO PHARMAGDR's earnings, one of the primary drivers of an investment's value.About BEXIMCO PHARMAGDR Financial Statements
BEXIMCO PHARMAGDR stakeholders use historical fundamental indicators, such as BEXIMCO PHARMAGDR's revenue or net income, to determine how well the company is positioned to perform in the future. Although BEXIMCO PHARMAGDR investors may analyze each financial statement separately, they are all interrelated. For example, changes in BEXIMCO PHARMAGDR's assets and liabilities are reflected in the revenues and expenses on BEXIMCO PHARMAGDR's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BEXIMCO PHARMAGDR REGS. Please read more on our technical analysis and fundamental analysis pages.
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients. Beximco Pharmaceuticals Limited was founded in 1976 and is headquartered in Dhaka, Bangladesh. Beximco Pharmaceuticals operates under Drug Manufacturers - Major classification in Germany and traded on Frankfurt Stock Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in BEXIMCO Stock
BEXIMCO PHARMAGDR financial ratios help investors to determine whether BEXIMCO Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BEXIMCO with respect to the benefits of owning BEXIMCO PHARMAGDR security.